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Lorin Loacker, MD,§ Anneliese Heinz, MD,ǁ and Corinna Velik-Salchner, MD*ǁ1Objective: Patients requiring extracorporeal membrane
oxygenation (ECMO) have a well-known bleeding risk and
the potential for experiencing possibly fatal thromboembolic
complications. Risk factors and predictors of transfusion
requirements during ECMO support remain uncertain. The
authors hypothesized that compromised organ function
immediately before ECMO support will inﬂuence transfusion
requirements.
Design: A prospective observational study.
Setting: A tertiary, single-institutional university hospital.
Participants: The study included 40 adult patients requir-
ing ECMO for intractable cardiac and respiratory failure
between July 2010 and December 2012. Blood samples were
taken before initiation of ECMO (baseline), after 24 and 48
hours on ECMO, and 24 hours after termination of ECMO.
Interventions: None.
Measurements and Main Results: Independent of veno-
arterial or veno-venous support, 26% of patients requir-
edZ2 packed red blood cells per day (PRBC/d) and 74% of
patients requiredo2 PRBC/d during ECMO. Requirements
ofZ2 PRBC/d during ECMO support were associated with
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Journal of Cardiothoat baseline and with impaired platelet function after 24
hours on ECMO. Platelet function, activated by thrombin
receptor-activating peptide stimulation, decreased by 30%
to 40% over time on ECMO. Receiver operating character-
istic curve analysis showed cut-off values for creatinine of
1.49 mg/dL (sensitivity 70%, speciﬁcity 70%; area under the
curve [AUC] 0.76, 95% conﬁdence interval [CI] 0.58-0.94), for
PT of 48% (sensitivity 80%, speciﬁcity 59%; AUC 0.69, 95%
CI 0.50-0.87), and for thrombin receptor-activating peptide
(TRAP) 32 U (sensitivity 90%, speciﬁcity 68%; AUC 0.76, 95%
CI 0.59-0.93).
Conclusions: The results of this study demonstrated that
increased creatinine levels and lower PT before ECMO and
secondary impaired platelet function signiﬁcantly increased
transfusion requirement.
& 2016 The Authors. Published by Elsevier Inc. All rights
reserved.
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blood impedance aggregometryBLEEDING AND THROMBOEMBOLIC complications inpatients undergoing mechanical circulatory support, such
as extracorporeal membrane oxygenation (ECMO), are com-
mon and associated with poor outcome.1,2 In adults, 2 types of
ECMO systems are used: veno-venous ECMO in respiratory
failure and veno-arterial ECMO in heart failure.3,4 On the one
hand, ECMO systems are associated with inﬂammatory
response and a hypercoagulable state. On the other hand, there
is a high risk for bleeding complications, particularly in
combination with increased anticoagulation and due to con-
sumption of coagulation factors and platelets.5 Unfractionated
heparin (UFH) is the most commonly administered anticoagu-
lant. The preferred method of anticoagulation monitoring
during ECMO support is serial measurement of activated
coagulation time (ACT).6,7 Bleeding and thromboembolic
complications often occur despite coagulant screening tests
and ACT measurement values in the target range.5The authors recently showed that short-term loss of high-
molecular–weight von Willebrand factor (HMW vWF) bands
occurs in all patients undergoing ECMO.8 Moreover, in the
same cohort the authors recently investigated various parame-
ters of blood coagulation, platelet, and organ function. Primary
endpoints were predictors of increased transfusion requirement
during ECMO support. Blood loss was estimated indirectly by
assessment of transfused packed red blood cells (PRBC).9 In
addition to various parameters of blood coagulation, the authors
determined metabolic parameters and organ function, which
also may inﬂuence transfusion requirement. Risk factors and
predictors of transfusion requirement during ECMO support
remain uncertain. The primary hypothesis was that compro-
mised organ function immediately before ECMO support will
inﬂuence transfusion requirement. The secondary hypothesis
was that coagulation changes during support will inﬂuence
transfusion requirement. The aim of this study was to present
real-life laboratory results during ECMO support that may
inﬂuence transfusion behavior of clinicians in such patients.
METHODS
This prospective, observational study was approved by the
Ethics Committee of the Medical University of Innsbruck
(UN4013;289/4.3). Because ECMO is an emergency interven-
tion and the patients usually are sedated, unconscious, and
already intubated before the decision for this intervention,
written informed consent was obtained after recovery in
survivors. The exclusion criterion was ageo18 years.
In the interest of clarity and perspective, data on changes in
vWF multimers, ristocetin cofactor activity, and factor VIII
activity are presented separately.8 Data that had not been the
subject of the previous study article, but were recordedracic and Vascular Anesthesia, Vol 30, No 3 (June), 2016: pp 692–701
PREDICTION OF TRANSFUSION REQUIREMENT DURING ECMO 693simultaneously during the study period, make up the content of
this article. Separate publication of these data was planned a
priori.
ECMO Management
ECMO management during the study period was as follows:
after induction of anesthesia with fentanyl, midazolam, and
rocuronium and before insertion of the ECMO cannula, 100 IU/
kg of UFH (Heparin Gilvasan; Gilvasan Pharma GmbH,
Vienna, Austria) was routinely administered. During ECMO
support, the ACT was maintained between 150 and 180
seconds (Hemochron Jr Signature, Accriva Diagnostics, San
Diego, CA) by continuous administration of UFH. Details on
ECMO support of these patients were described previously.8
Study Protocol
Blood sampling and recording of administered blood
products were performed at the following 4 time points: before
initiation of ECMO support (baseline, before administration of
heparin and before insertion of cannulae), after 24 hours on
ECMO support, after 48 hours on ECMO support, and
24 hours after ECMO termination. Blood samples were
obtained through a 3-Fr radial catheter (Becton Dickinson,
Swindon, UK) inserted for clinical indication. To diminish
laboratory errors, more than 3 mL of blood were discarded. For
analysis of coagulation parameters and rotational thromboelas-
tometry (ROTEM; Tem International GmbH, Basel, Switzer-
land), samples were put in 3-mL tubes containing 0.3 mL
(0.106 mol/L) of buffered (pH 5.5) sodium citrate (Sarstedt,
Nümbrecht, Germany). For platelet function testing, samples
were put in 2.7-mL tubes containing hirudin (Sarstedt, Nüm-
brecht, Germany).
Laboratory Analysis
Hemoglobin (reference range: 130-177 g/L), platelet count
(150-380 g/L), and white blood cell count (4-10 g/L) were
measured in 2.7-mL tubes containing 1.6 mg ethylenediami-
netetraacetic (EDTA) acid/mL blood (Sarstedt, Nümbrecht,
Germany) using the whole blood counter Sysmex XE-5000
(Sysmex, Norderstedt, Germany).
Prothrombin time (Thromborel S; reference range: 70%-
130%), activated partial thromboplastin time (PTT) (Pathromtin
SL; reference range: 26-37 s), antithrombin (Berichrom Antith-
rombin III; reference range: 79%-112%), ﬁbrinogen concen-
tration (Multiﬁbren U; reference range: 210-400 mg/dL) and
D-dimers (Innovance D-dimer test; reference range: 0-500 mg/L)
were determined using assays from Siemens Healthcare,
Marburg, Germany.
ROTEM was performed with the ROTEM Delta coagula-
tion analyzer (Tem Innovations, Munich, Germany), which is
based on the thromboelastograph system (Haemonetics, Brain-
tree, MA). The measurement principle and interpretation of
results are described in detail elsewhere.10 In each case the
ROTEM device was checked for proper function using a
control sample (ROTROL; Tem Innovations, Munich,
Germany) according to the manufacturer’s recommendations.
All tests were performed following the ROTEM manufacturer’s
speciﬁcations within 30 minutes after collecting the sampleusing the STARTEM (calcium chloride), INTEM (ellagic acid,
does not contain heparinase), EXTEM (tissue factor, heparin-
ase), and FIBTEM (containing the platelet-blocking substance
cytochalasin D and heparinase) assays (Tem Innovations,
Munich, Germany). The following variables were determined
for the INTEM and EXTEM assays: coagulation time (CT)
(reference range EXTEM 38-79 sec, INTEM 100-240 sec), clot
formation time (reference range EXTEM 34-179 sec, INTEM
30-110 sec), maximum clot ﬁrmness (MCF) (reference range
EXTEM and INTEM 50-72 mm), α angle (reference range
EXTEM 631-831, INTEM 701-831), and lysis index 30 minutes
(LI30) and 60 minutes (LI60) (reference rangeZ85% for both,
describing the percentage of maximum clot strength present at
30 and 60 minutes). From the FIBTEM assay (allowing
ﬁbrinogen’s contribution to clot strength to be measured), the
MCF was recorded (FIBTEM MCF; reference range 9-25 mm).
Platelet function testing was performed using point-of-care
whole blood impedance aggregometry (WBA) (Multiplate
analyzer; Roche Diagnostics GmbH, Vienna, Austria). The
Multiplate measurement principle and interpretation of results
are described in detail elsewhere.11 The following Multiplate
tests were ordered from the manufacturer and performed
according to the manufacturer’s speciﬁcations: TRAPtest
([M-TRAP], containing thrombin receptor-activating peptide;
reference range: 42-144 U), ASPItest ([M-AA], containing
arachidonic acid; reference range: 75-136 U), and adenosine
diphosphate (ADP) test ([M-ADP], containing ADP; reference
range: 53-122 U).
Thrombin generation was determined as described previ-
ously.12 Blood samples were centrifuged at 2,200 g over 15
minutes to obtain platelet-poor plasma. Platelet-poor plasma
was stored in aliquots at –801C for further analysis. Thrombo-
grams were measured using the Calibrated Automated Throm-
bogram system (Thrombinoscope, Maastricht, Netherlands)
with a fully automated, computer-controlled ﬂuorometric
microplate reader and speciﬁed software. Each thrombin
generation was performed in duplicate, with the calibrator
being added in a third well according to the manufacturer’s
recommendations (CL well). This process guaranteed correc-
tion for color of the tested plasma sample. The ﬁnal concen-
trations of tissue factor and phospholipids were 5 pmol/L and 4
mmol/L, respectively. The following parameters were analyzed:
lag time (min), time-to-peak (min), peak high (nmol), and
endogenous thrombin potential (nmol  min).
Creatinine (CREP2 assay; reference range: 0.67-1.17 mg/
dL), urea (UREAL; 18-55 mg/dL), bilirubin (BILT2; 0-1.28
mg/dL), glutamate oxalacetal transaminase (ASTEM; 10-50
U/L), glutamate pyruvate transaminase (ALTPM; 10-50 U/L),
gamma glutamyl transferase (GGT-2; 20-71 U/L), lactate
dehydrogenase (LDHI2; 100-250 U/L), and lactate (LACT2;
4.5-19.8 mg/dL) were measured using the tests from Roche
(Mannheim, Germany) as previously mentioned.Transfusion Practice and Deﬁnition of Increased
Requirement of Packed Red Blood Cells Per Day
on ECMO
Patients were treated according to clinical routine. Anes-
thesiologists, intensivists, and surgeons were blinded to the
TAUBER ET AL694laboratory results. According to clinical routine, PRBC
depleted of leukocytes were transfused when hemoglobin
was below 85 g/L. Apheresis platelet concentrates were
administered when the platelet count was below 70 G/L.1,5
Fresh frozen plasma (FFP) or prothrombin complex concentrate
(PCC) was given in patients demonstrating reduced PT (o1.5
of the normal value). Fibrinogen concentrate was administered
in the case of ﬁbrinogen values lower than 250 mg/dL, or
FIBTEM-MCF values lower than 12 mm.
The following administered blood products were recorded
for every day on ECMO: units of PRBC, FFP, apheresis
platelet concentrates, PCC (Prothromplex Total 600 IU; Baxter,
Vienna, Austria), and ﬁbrinogen concentrate (mg) (Haemo-
complettan; CSL Behring, Vienna, Austria).
Increased transfusion requirement during ECMO was
deﬁned as a PRBC/d requirement ranging over the third
quartile of the study population, which in this study referred
to Z2U PRBC/d. Patients receivingo2U PRBC/d were
pooled in the moderate transfusion requirement group. Com-
parable amounts of required PRBC/d on ECMO are reported in
the literature.1,13-16 Because the study start was predeﬁned as
ECMO support start, blood products given in surgical bleeding
situations before ECMO start were not within the scope of this
study and were not included in the analysis.Statistical Analysis
The a priori power analysis resulting in a planned sample
size of 40 patients was performed to address the research
question investigated in the vWF study.8 However, an a
posteriori power analysis was conducted for this study using
the areas under the curve (AUCs) of the receiver operating
characteristic (ROC) curves. This analysis revealed that a
sample size of 38 patients, in which one-fourth of all patients
required excessive transfusion (ie, 10 v 28 patients, which
matched the numbers observed in this study), allowed detection
of a difference in the area under the ROC curve of 0.80 versus
0.50 (meaning no predictive power) on a signiﬁcance level of
α = 0.05 with a power of 80%. Thus, in short, the authors were
able to detect an AUC of at least 0.80 with a conﬁdence of at
least 80% in this study.
All patient characteristics and laboratory measurements
were analyzed descriptively (absolute and relative frequency
for qualitative, mean, and standard deviation [SD] for quanti-
tative data) overall and stratiﬁed for time points. Student’s t-test
or Fisher’s exact test (for dichotomous data) was performed to
test for differences between groups.
To test for differences in means among the 4 time points,
univariate one-way repeated-measures analysis of variance was
performed for each coagulation and laboratory parameter. To
account for possible sphericity violation among time points, p
values were corrected according to the Greenhouse-Geisser
method. If the p value of the within-subject effect time point
was statistically signiﬁcant (po 0.05), pairwise comparisons
(time points: baseline v 24 h on ECMO; baseline v 48 h on
ECMO support; baseline v 24 h after ECMO support; and 24 v
48 h on ECMO support) were calculated with paired t tests as
post hoc tests. Bonferroni correction for multiple testing
was used.Univariate analysis of coagulation and laboratory values
comparing patients with moderate PRBC/d transfusion require-
ment and patients with increased PRBC/d requirement on
ECMO was performed for baseline values and values after
24 hours on ECMO using Student’s t-test. Because mean
values for creatinine at baseline, PT at baseline, and M-TRAP
after 24 hours on ECMO demonstrated associations with
transfusion requirement in these univariate tests (signiﬁcant at
po 0.05 for creatinine and M-TRAP; PT marginally non-
signiﬁcant [p = 0.055], but deemed clinically relevant), the
authors further investigated the potential of these parameters to
predict increased PRBC/d requirement on ECMO. The associ-
ation among these 3 parameters and transfusion requirement
was conﬁrmed in a multivariate logistic regression model.
Furthermore, the authors constructed ROC curves (univariately
and multivariately for the probability score of the logistic
regression) and calculated the AUC, speciﬁcity, positive
predictive value, negative predictive value, and accuracy for
various cut-off values, including the value for which the sum of
sensitivity and speciﬁcity was highest. The 95% conﬁdence
interval (CI) was calculated for all these parameters according
to the DeLong method for AUC and with bootstrapping on
2,000 replications for the other performance measures. A
signiﬁcance level of α = 0.05 (2-sided) was used. Statistical
analyses were performed using SPSS, version 22.0 (IBM Corp,
Armonk, NY) and R, version 3.1.1 (R Foundation, Vienna,
Austria).
RESULTS
Demographics and Procedural Data
Forty adult patients requiring ECMO support due to
refractory cardiac and/or pulmonary failure were prospectively
enrolled in this observational study. Two patients died within
24 hours after initiation of ECMO and were excluded from
analysis. Thus, data from 38 patients were available for
analysis (veno-arterial ECMO, n = 26; veno-venous ECMO,
n = 12). Calculation of the requirement of the number of
PRBC/d per patient during ECMO support demonstrated that 2
PRBC/d per patient fell over the 75th percentile and led the
authors to deﬁne moderate (o2 PRBC/d, n = 28) and increased
(42 PRBC/d, n = 10) transfusion requirement groups. Patients
with moderate and increased transfusion requirement showed
no differences in demographics, antiplatelet therapy within 5
days before surgery, ﬂow characteristics after 24 hours on
ECMO, and type of ECMO support (Table 1). Because there
were no differences between veno-arterial and veno-venous
ECMO concerning cannula type, vascular access, pump type,
or several laboratory values (data not shown), data were
combined for analysis. For the sake of clarity and conciseness,
only signiﬁcant and clinically relevant data are detailed. Further
information is included in Tables 2 to 4 and in Supplementary
Tables 1 to 3.
Laboratory Data (Combined Data from Both Groups
Over All Measurement Points)
Blood Cell Count and Coagulation Values
Platelet count (p ¼ 0.001) changed over time. Compared
with baseline, platelet count decreased after 24 hours
Table 1. Demographics and Procedural Data
Moderate Transfusion Requirement
(o2 Packed Red Blood Cells/d) n ¼ 28 (74%)
Increased Transfusion Requirement
(Z2 Packed Red Blood Cells/d) n ¼ 10 (26%) p Value
Demographics
Age (yr) 52  14 50  15 0.679
Body weight (kg) 72  18 77  12 0.317
Body height (cm) 172  9 170  7 0.442
Body surface area 1.8  0.2 1.9  0.1 0.521
Antiplatelet therapy within 5 days before surgery
n ¼ 10/28 (36%) n ¼ 3/10 (30%) 1.000
Flow characteristics after 24 h on ECMO
Flow (L/min) 4.5  0.9 4.2  0.7 0.362
Rates per minute 3665  519 3507  532 0.425
Veno-venous ECMO (n ¼ 12/32%)
n ¼ 8/28 n ¼ 4/10 0.694
Veno-arterial ECMO (n ¼ 26/68%)
n ¼ 20/28 n ¼ 6/10 0.694
NOTE. Results of univariate analysis of demographics, antiplatelet therapy within 5 days before surgery, ﬂow characteristics after 24 hours on
extracorporeal membrane oxygenation, and kind of support comparing patients with moderate and increased transfusion requirement during
extracorporeal membrane oxygenation using Student’s t-test or Fisher’s exact test (statistically signiﬁcant: p o 0.05). Data are presented as
mean  SD or frequencies.
Abbreviation: ECMO, extracorporeal membrane oxygenation.
PREDICTION OF TRANSFUSION REQUIREMENT DURING ECMO 695(po 0.001) and 48 hours (po 0.001) on ECMO. After
termination of ECMO, values did not differ from baseline.
Hemoglobin values did not change over time (p ¼ 0.249). PT
signiﬁcantly changed over time (po 0.0001), demonstrating
higher values after 24 hours (p ¼ 0.012), 48 hours on ECMO
(po 0.001), and after termination of ECMO (po 0.004) than
at baseline. PTT did not change signiﬁcantly over time.
Fibrinogen values increased over time (p ¼ 0.012), but no
differences between individual measurement points could be
detected. D-dimers remained unchanged over time. ACT values
did not differ between 24 hours and 48 hours on ECMO (see
Table 2).
ROTEM Parameters
EXTEM-CT did not change over time (p ¼ 0.111).
EXTEM-MCF (po 0.0001) changed over time. Compared
with baseline, EXTEM-MCF was lower after 24 hours
(po 0.0001) and 48 hours (po 0.0001) on ECMO. No
hyperﬁbrinolysis was detected (see Supplementary Table 1).
INTEM-CT did not change over time (p ¼ 0.677). INTEM-
MCF changed signiﬁcantly over time (po 0.0001). INTEM-
MCF was lower after 24 hours (po 0.0001) and 48 hours
(po 0.0001) on ECMO. There were no signs of hyper-
ﬁbrinolysis.
FIBTEM-MCF did not change over time (p ¼ 0.168) (see
Supplementary Table 1).
Multiplate Whole Blood Aggregometry
M-TRAP (p ¼ 0.013), M-ADP (p ¼ 0.008), and M-AA
(p ¼ 0.014) changed over time. Compared with baseline, values
were lower after 24 hours on ECMO (M-TRAP: p ¼ 0.004;
M-ADP: p ¼ 0.004; M-AA: p ¼ 0.028). After 48 hours on
ECMO, M-TRAP did not differ from baseline (p ¼ 0.184);
M-ADP (p ¼ 0.016) and M-AA (p ¼ 0.044) were still lower than
baseline values. M-TRAP, M-ADP, and M-AA reached baseline
values after weaning from ECMO (see Table 3).Thrombin Generation
Peak high (p ¼ 0.824) and endogenous thrombin potential (p
¼ 0.903) did not change over time. Lag time (p ¼ 0.012) and
time-to-peak (p ¼ 0.008) changed over time. Compared with
baseline, lag time values were higher after ECMO support (p ¼
0.004). In contrast, time-to-peak values did not differ signiﬁcantly
in any pairwise comparison of measurement points (see Table 4).
Other Laboratory Results
L-lactate levels changed over time (po 0.0001). Compared
with baseline, values were lower after 24 hours (po 0.0001)
and 48 hours (po 0.0001) on ECMO and remained lower
after ECMO termination (po 0.0001). Urea increased over
time (p ¼o 0.001), demonstrating higher values after ECMO
(p ¼ 0.004) than at baseline. Glutamate oxalacetal transaminase
changed over time (p ¼ 0.027), without reaching signiﬁcance
for any pairwise comparison of measurement points. Creati-
nine, bilirubin, glutamate pyruvate transaminase, gamma glu-
tamyl transferase, and lactate dehydrogenase did not change
over time (see Supplementary Table 2).
Transfusion Requirements During ECMO
All patients required blood transfusions. PRBC calculated
per day on ECMO ranged from 0.1 to 7.6 (median 1.30;
interquartile range 1.0-2.0). Seventy-four percent (n ¼ 28)
neededo2 PRBC/d (moderate transfusion requirement).
Increased transfusion requirement (Z2 PRBC/d) was seen in
26% (n ¼ 10) of patients. Patients with increased PRBC/d
requirement also received more platelet concentrates. In con-
trast, amounts of administered FFP, ﬁbrinogen concentrates,
and PCC were comparable between groups (Table 5).
Univariate Analysis Comparing Patients With
Moderate and Increased Transfusion Requirement
After 24 hours on ECMO, hemoglobin was higher in
patients with moderate transfusion requirement (mean  SD),
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TAUBER ET AL696namely 96  11g/dL compared with patients with increased
transfusion requirement (88  9 g/dL; p ¼ 0.025). PTT after
24 hours on ECMO was lower in patients with moderate
transfusion requirement (57  18 s) than in patients with
increased transfusion requirement (79  47 s; p ¼ 0.040).
M-TRAP after 24 hours on ECMO was higher in patients with
moderate transfusion requirement (44  23 U) than in patients
with increased transfusion requirement (24  12 U; p ¼
0.002). Creatinine was lower in patients with moderate trans-
fusion at baseline (1.2  0.5 mg/dL) and after 24 hours on
ECMO (1.3  0.69 mg/dL) compared with patients with
increased transfusion requirement at baseline (2.3  1.5 mg/
dL; p ¼ 0.004) or after 24 hours on ECMO (2.2  1.1 mg/dL;
p4 0.002) (Table 6, see Supplementary Table 3).
ROC Analysis and Results of Multivariate Logistic
Regression on Prediction of Increased Transfusion
Requirement
Baseline creatinine, baseline PT, and M-TRAP after 24
hours on ECMO were used to investigate the potential to
predict moderate and increased transfusion requirement. PT
was included despite being marginally nonsigniﬁcant in a
univariate Student’s t-test, but deemed clinically relevant (see
Table 6). PTT values after 24 hours on ECMO were excluded
(heparin anticoagulation). Hemoglobin values after 24 hours on
ECMO were excluded; all patients received PRBC (see
Supplementary Table 3).
ROC analysis showed cut-off values to predict increased
transfusion requirement for creatinine, namely 1.49 mg/dL
(sensitivity 70%, speciﬁcity 70%; AUC 0.76, 95% CI 0.58-
0.94), for prothrombin time 48% (sensitivity 80%, speciﬁcity
59.3%; AUC 0.69, 95% CI 0.50-0.87), and for M-TRAP 32 U
(sensitivity 90%, speciﬁcity 68%; AUC 0.76, 95% CI 0.59-
0.93) (Table 7, Fig 1). Combined multivariate ROC analysis of
all 3 parameters showed an AUC of 0.9 (95% CI 0.79-1.00)
(see Fig 1). Multivariate analysis demonstrated the 3 parame-
ters together to have a highly signiﬁcant combined effect on
increased transfusion requirement (po 0.001), with adjusted
odds ratios for creatinine being 10.7 (95% CI 0.89-127.64; p ¼
0.061), for PT 0.93 (95% CI 0.86-0.99; p ¼ 0.036), and for M-
TRAP 0.90 (95% CI 0.80-1.00; p ¼ 0.048).
DISCUSSION
In a prospective cohort of 40 adults treated at the authors’
institution, predictors of transfusion requirement during ECMO
support were investigated. Blood loss was estimated indirectly
by assessing transfused PRBC. Independently of veno-arterial
or veno-venous support, 26% of patients required Z2 PRBC/d
and 74% of patients requiredo2 PRBC/d during ECMO.
Requirement ofZ2 PRBC/d during ECMO support was
associated with higher creatinine levels and lower PT at
baseline. Platelet function, measured using Multiplate WBA,
decreased by 30% to 40% over time. This effect was more
pronounced in patients receivingZ2 PRBC/d than in patients
administeredo2 PRBC/d. The platelet count was cut nearly in
half during ECMO support. Simultaneously, MCF measured
using thromboelastometry decreased. Within 24 hours after
weaning from ECMO, platelet count, platelet function, and
Table 3. Results of Multiplate Whole Blood Aggregometry
Variables (Normal Range) Baseline
24 h on
ECMO
48 h on
ECMO
24 h after
ECMO Overall p
p (Baseline v 24 h
on ECMO)
p (Baseline v 48 h
on ECMO)
p (Baseline v 24 h
after ECMO)
p (24 h v 48 h
on ECMO)
Multiplate-TRAP
(42-144 U)
57  35 38  21 37  29 54  33 0.013 0.004 0.184 0.868 1
Multiplate-ADP
(53-122 U)
33  32 16  13 18  17 30  29 0.008 0.004 0.016 0.392 1
Multiplate-AA
(75-136 U)
30  32 15  16 15  15 36  32 0.014 0.028 0.044 0.976 1
NOTE. Data are presented as mean  SD. Overall p values are from univariate one-way repeated-measures analysis of variance corrected
according to the Greenhouse-Geisser method; post hoc p values are from paired t tests corrected for multiple testing according to the Bonferroni
method. p values are considered signiﬁcant when p o 0.05.
Abbreviations: ECMO, extracorporeal membrane oxygenation; TRAP, thrombin receptor-activating peptide; ADP, adenosine diphosphate; AA,
arachidonic acid.
PREDICTION OF TRANSFUSION REQUIREMENT DURING ECMO 697MCF returned to baseline values. Initiation of clot formation
(ROTEM CT) was not affected by ECMO support. Fibrinogen
concentration and ﬁbrin polymerization even enhanced during
ECMO support. Hyperﬁbrinolysis did not occur. PT signiﬁ-
cantly changed over time, showing improvement after 24 and
48 hours and termination of ECMO support. PTT and thrombin
generation (IIa) measured after the method of Hemker17 did not
change over time, although patients were anticoagulated with
UFH. Previously demonstrated loss of HMW vWF multimer
bands during ECMO support did not inﬂuence transfusion
requirement.8
Reported numbers of daily required PRBC during ECMO in
this study were independent of veno-arterial and veno-venous
support. This ﬁnding was in accordance with published
data.13,14 Of note, in other studies,13,14 numbers of transfused
platelet concentrates were higher than at the authors’ institu-
tion. The lower target platelet count at the authors’ institution
(70 G/L v 100G/L) may have contributed, at least partly, to this
ﬁnding. Administration of blood products differed. In selected
cases, the authors used ﬁbrinogen concentrates and PCC.
Administration of blood products did not result in any
thromboembolic complication.
Depending on severity of disease, circulatory and respira-
tory restriction lead to renal and hepatic impairment and
shock.18-21 ECMO support is reserved for patients with end-
stage cardiac and pulmonary failure. Increased creatinine
plasma levels are an expression of renal disturbance in these
severely diseased patients. Moreover, a high creatinine level
is a predictor of bleeding (see Fig 1). Patients with a high
PRBC requirement showed increased creatinine values (1.2 v
2.3 mg/dL) before ECMO support. This ﬁnding persisted inTable 4. Thrombin Generation
Variables (Normal Range) Baseline
24 h on
ECMO
48 h on
ECMO
24 h after
ECMO Ove
Peak high (nmol) 197  88 184  96 168  92 193  106 0.8
ETP (nmol  min) 996  446 905  417 900  471 905  494 0.9
Lag time (min) 3.6  2.3 3.1  1.1 3.7  2.2 5.1  2.4 0.0
Time-to-peak (min) 6.3  3.2 5.7  2.5 6.4  2.5 7.8  2.5 0.0
NOTE. Data are presented as mean  SD. Overall p values are from u
according to the Greenhouse-Geisser method; post hoc p values are from p
method; p values are considered statistically signiﬁcant when po 0.05.
Abbreviations: ECMO, extracorporeal membrane oxygenation; ETP, endselected patients despite recovery of circulation and additional
continuous veno-venous hemoﬁltration. Lower PT before
ECMO likely reﬂected liver congestion due to low cardiac
output and reduced synthetic capacity.18,21 Continuously
improving PT values during ECMO support supposedly indi-
cated recovery.22
Platelet function and count are critically dependent on
numerous factors, including severity of disease and treatment
modality. Decreased adhesion and aggregation in patients with
renal impairment are due to a disturbance in platelet α granules
and an impaired synthesis of thromboxane A2.
20 Enlargement
of the liver and spleen due to venous hypertension inﬂuences
platelet count via pooling. Patients in this study demonstrated a
signiﬁcant decrease in platelet function during ECMO. M-AA
and M-ADP were cut nearly in half, and M-TRAP was reduced
by 30%. Attenuation of platelet function after 24 hours on
ECMO measured using M-TRAP was more pronounced in
patients with increased transfusion requirement. TRAP is the
most potent activator of platelets in vitro and it mimics in vivo
thrombin effect. Thrombin induces activation of GPIIb-IIIa and
is a powerful ampliﬁer of platelet function.23 The strong
aggregation effect of M-TRAP is not sensitive to
cyclooxygenase-1 inhibitors or ADP-receptor-blocking agents,
such as clopidogrel.24 Because thrombin is the most potent
activator of platelets, a reduced TRAPtest ﬁnding may indicate
an overall impaired platelet function.25
Activation of platelets is one of the primary events occurring
after blood comes into contact with artiﬁcial surfaces in oxy-
genators, tubes, pumps, cannulae, and other equipment. Oxy-
genators have a large blood-contacting surface (up to 2-3 m2)
and are presumed to play a major role in platelet activation andin Platelet-Poor Plasma
rall p
p (Baseline v 24 h
on ECMO)
p (Baseline v 48 h
on ECMO)
p (Baseline v 24 h
after ECMO)
p (24 h v 48 h
on ECMO)
24 1 1 1 1
03 0.780 1 1 1
12 1 0.436 0.004 0.692
08 0.960 1 0.084 1
nivariate one-way repeated-measures analysis of variance corrected
aired t tests corrected for multiple testing according to the Bonferroni
ogenous thrombin potential.
Table 5. Comparison of Blood Products Required by Patients Undergoing Extracorporeal Membrane Oxygenation With Moderate and Increased
Transfusion Requirement of Packed Red Blood Cells Per Day
Patients with Moderate Transfusion Requirement
(o2 Packed Red Blood Cells/d) n ¼ 28 (74%)
Patients with Increased Transfusion Requirement
(Z2 Packed Red Blood Cells/d) n ¼ 10 (26%) p Value
Packed red blood cells/d 1.1  0.4 3.2  1.8 0.006
Fresh frozen plasma/d 0.5  1.0 0.6  0.9 0.873
Apheresis platelet
concentrates/d
0.4  0.5 0.8  0.8 0.002
Fibrinogen concentrate (mg/d) 230  41 330  66 0.607
Prothrombin complex
concentrate (U/d)
15  66 96  206 0.250
NOTE. Data are presented as mean  SD.
TAUBER ET AL698consumption during extracorporeal circulation.26 Paul
et al26 quantiﬁed platelet adhesion to artiﬁcial surfaces by using
Western blot antibodies directed against the platelet receptor
GPIIb-IIIa (CD 41) and demonstrated the strong inﬂuence of
coated surfaces. Their study was limited to 120 minutes. All
oxygenators and tubes used in the study presented here had a
commercially available albumin-heparin composition surface.
Urlesberger et al27 investigated the effect on coagulation of
heparin-coated versus noncoated systems in pigs undergoing
ECMO for 24 hours. Coated systems demonstrated delayed
clotting activation, but after 6 hours no differences between
groups were detectable. In the study presented here, platelet
count continuously decreased in both groups during ECMO. InTable 6. Results of Univariate Analysis (p o 0.05) of Coagulation and Lab
Moderate and Increased Transfusion Requirement
Moderate Transfusion Requi
(o2 Packed Red Blood Cells/d) n
Creatinine, mg/dL (baseline) 54  22
Prothrombin time, % (baseline) 1.2  0.5
Multiplate TRAP, U (24 h on ECMO) 44  23
NOTE. Data are presented as mean  SD. Prothrombin time was incl
relevant; p values o0.05 are considered signiﬁcant.
Abbreviations: TRAP, thrombin receptor-activating peptide; ECMO, extra
Table 7. Sensitivity, Speciﬁcity, and Area Under the Curve for Selected
During Extracorporeal Membr
Variables Threshold TP TN FP FN Sensitivity
Creatinine (mg/dL) at baseline 1.0 9 11 16 1 90% (70
1.3 8 15 12 2 80% (50
1.6 5 21 6 5 50% (20
1.49* 7 19 8 3 70% (40
Prothrombin time (%) at baseline 60.0 9 10 17 1 90% (70
50.0 8 15 12 2 80% (50
40.0 5 19 8 5 50% (20
48.0* 8 16 11 2 80% (50
Multiplate TRAP (U) after 24 hours
on ECMO
32.0 9 17 8 1 90% (70
29.0 7 17 8 3 70% (40
26.0 4 20 5 6 40% (10
32.0* 9 17 8 1 90% (70
Abbreviations: TP, true-positive; TN, true-negative; FP, false-positive
predictive value; AUC, area under the curve; TRAP, thrombin receptor-act
*“Best” cut-off value (ie, sum of sensitivity and speciﬁcity is highest), baccordance with these experimental ﬁndings, patients demon-
strated decreased platelet count during ECMO. Thrombocytope-
nia during ECMO was accompanied by a decrease in maximum
clot ﬁrmness (MCF) and an increase in clot formation time.
Remarkably, EXTEM MCF values remained within the normal
(lower) range on ECMO, but INTEM MCF values were below
the normal range during support. In contrast, FIBTEM MCF
values and ﬁbrinogen concentrations increased during ECMO
and remained within the upper normal range after weaning from
ECMO. Thromboelastometry is highly dependent on ﬁbrinogen.
The increase in ﬁbrinogen and FIBTEM MCF during support is
likely due to activation of the inﬂammatory system. Inﬂamma-
tion itself provokes activation and consumption of the clottingoratory Values Used to Investigate Discriminatory Power to Predict
During Extracorporeal Membrane Oxygenation
rement
¼ 28 (74%)
Increased Transfusion Requirement
(Z2 Packed Red Blood Cells/d) n ¼ 10 (26%) p Value
39  19 0.055
2.3  1.5 0.004
24  12 0.002
uded despite being marginally nonsigniﬁcant, but deemed clinically
corporeal membrane oxygenation.
Thresholds Predicting Requirement of Z2 Packed Red Blood Cells/d
ane Oxygenation Support
(95% CI) PPV (95% CI)
Speciﬁcity
(95% CI) NPV (95%CI) AUC (95% CI)
-100) 36% (28-46) 41% (22-59) 92% (75-100) 0.76 (0.58-0.94)
-100) 40% (28-56) 56% (37-74) 88% (74-100)
-80) 46% (22-75) 78% (63-93) 81% (71- 92)
-100) 47% (29-67) 70% (52-85) 86% (70-100)
-100) 35% (27-44) 37% (19-56) 91% (71-100) 0.69 (0.50-0.87)
-100) 40% (29-56) 56% (37-74) 88% (75-100)
-80) 39% (18-62) 70% (52-85) 79% (68-91)
-100) 42% (29-58) 59% (41-78) 89% (76-100)
-100) 53% (41-71) 68% (48-84) 94% (84-100) 0.76 (0.59-0.93)
-100) 47% (29-67) 68% (48-84) 85% (72-100)
- 70) 44% (17-75) 80% (64-92) 77% (68-88)
-100) 53% (41-71) 68% (48-84) 94% (84-100)
; FN, false-negative; PPV, positive predictive value; NPV, negative
ivating peptide.
olded in these rows for emphasis.
Fig 1. Area under the receiver operating characteristic (ROC) curve for creatinine at baseline (A), for prothrombin at baseline (B), for platelet function
after 24 hours on extracorporeal membrane oxygenation (C) measured using thrombin receptor-activating peptide time (TRAP) and combined
multivariate ROC analysis of all 3 parameters (D), predicting increased transfusion requirement during support by extracorporeal membrane
oxygenation.
PREDICTION OF TRANSFUSION REQUIREMENT DURING ECMO 699system.28-30 Nair et al31 reported similar results in platelet count
and ROTEM values during ECMO support over time. After
shifting from ECMO to a ventricular assist device, Huang et al32
demonstrated improved coagulation in all patients. Platelet count
and thromboelastographic maximal amplitude nearly doubled
within 24 hours after bridging to the ventricular assist device,
indicating that the ECMO system itself plays an important role
in inducing coagulation disturbances.32
Despite anticoagulation with UFH, which maintained an
ACT between 150 and 180 seconds, INTEM CT and PTT
values did not change over time. PTT values were highest
before ECMO, even before the ﬁrst dose of UFH. PT valueswere most compromised before ECMO. Combes et al22
reported an association between PTo50% and poor outcome.
In accordance therewith, the authors of the study presented here
observed signiﬁcant PT changes over time. PT and PTT
continuously improved during ECMO, which may have been
inﬂuenced by compromised liver function due to the underlying
cardiopulmonary shock and following organ recovery.
Study Limitations
Decreased clot strength after 24 and 48 hours on ECMO also
may have been affected by F:XIII deﬁciency, which was not
determined in this study population. Certainly none of the patients
TAUBER ET AL700developed ﬁbrinolysis, so there is no indirect evidence for a F:XIII
deﬁciency. Hemolysis also may have inﬂuenced PRBC require-
ment. Because free hemoglobin was not measured during the study
period, hemolysis during ECMO support cannot be excluded. As
the authors recently demonstrated, ECMO induces short-term loss
of HMW vWF multimers.12 The effect was similar in patients with
moderate and increased PRBC requirement; data were not included
in the calculation for identiﬁcation of predictors of PRBC require-
ment. Nevertheless, loss of HMW vWF multimers may have
inﬂuenced blood loss and transfusion requirement. Anemia and
thrombocytopenia during ECMO support may have inﬂuenced the
results of WBA, although the authors considered its effects below
threshold. Results of platelet function tests were judged clinically
relevant, although some experts may not approve routine platelet
function testing in ECMO patients. Thrombelastography/thrombe-
lastometry considered imprecise and not dependable by many
experts, even when quality controls are performed rigorously. Last
but not least, the relatively small number of study participants may
have led to underestimation and overestimation of at least some
ﬁndings.CONCLUSION
ECMO support improves outcome in patients with cardiac
and pulmonary failure. It inﬂuences organ systems, inﬂamma-
tory response, and clotting activity. This study’s results
demonstrated that increased creatinine levels and lower PT
before ECMO and secondary impaired platelet function sig-
niﬁcantly increased transfusion requirement. The authors con-
cluded that special attention to creatinine, PT, and platelet
function is indicated. These parameters, preferably in combi-
nation, are excellent predictors of transfusion requirement.
High transfusion requirement increases morbidity and mortal-
ity in patients who undergo ECMO.16 The data presented here
indicated that timely administration of ECMO support may reduce
transfusion requirement and consequently inﬂuence outcome.
APPENDIX A. SUPPLEMENTARY MATERIAL
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1053/j.jvca.2016.
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